Niagen Bioscience to Present at Nasdaq X LD Micro Summit — Niagen Bioscience, Inc.

Event summary

Niagen Bioscience (NASDAQ: NAGE) will present at the Nasdaq X LD Micro Inaugural SF Summit on September 9, 2026.
CFO Ozan Pamir will deliver a 15-minute presentation followed by a breakout session with institutional investors.
The company's consumer supplement, Tru Niagen, is the top NAD+ boosting oral supplement in the U.S. by revenue.
Niagen Bioscience's subsidiary, NAD Pharmaceuticals Corp., is researching NB4168 for accelerated aging and rare genetic diseases.

The big picture

Niagen Bioscience's participation in the Nasdaq X LD Micro Summit underscores its strategic focus on engaging institutional investors amid growing interest in healthy aging and NAD+ science. The company's market-leading position in NAD+ boosting supplements positions it well to capitalize on the expanding healthspan market, though it faces competition and regulatory scrutiny in its pharmaceutical research efforts.

What we're watching

Investor Sentiment: How the presentation will impact investor confidence in Niagen Bioscience's growth prospects.
Product Expansion: Whether the company can sustain its market leadership in NAD+ boosting supplements.
Research Progress: The pace at which NAD Pharmaceuticals Corp. advances NB4168 through clinical development.